23andMe® is a personal genetics company that provides genome analysis services via its easy-to-use and affordable at-home DNA-collection kit. While many direct-to-consumer genetics companies, including 23andMe, have been around for about a decade, 23andMe became the first company to receive FDA authorization to market direct-to-consumer genetic health risk reports in April 2017. To date, the company has received $491 million in funding, including a recent $250 million equity round led by Sequoia Capital, which had a reported pre-money valuation of $1.5 billion.
